Melinta Therapeutics (MLNTQ) Stock Price, News & Analysis

Company Overview

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is based in Morristown, New Jersey. On December 27, 2019, Melinta Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.11 to $0.11
• 52-Week Range: $0.06 to $8.60
• Volume: 32,900 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MLNTQ Stock Analysis - Frequently Asked Questions

How have MLNTQ shares performed this year?

Melinta Therapeutics' stock was trading at $0.11 at the beginning of 2025. Since then, MLNTQ shares have increased by 0.0% and is now trading at $0.11.
View the best growth stocks for 2025 here.

How do I buy shares of Melinta Therapeutics?

Shares of MLNTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MLNTQ
• CIK: N/A
• Web: www.melinta.com
• Phone: 908-617-1309
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A